Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Account Payables (2017 - 2019)

VYNE Therapeutics (VYNE) has disclosed Change in Account Payables for 3 consecutive years, with $779000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Change in Account Payables rose 33.16% year-over-year to $779000.0, compared with a TTM value of $481000.0 through Dec 2019, down 41.7%, and an annual FY2019 reading of $481000.0, down 41.7% over the prior year.
  • Change in Account Payables was $779000.0 for Q4 2019 at VYNE Therapeutics, up from -$1.7 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.6 million in Q2 2018 and bottomed at -$2.4 million in Q3 2018.
  • Average Change in Account Payables over 3 years is $160500.0, with a median of $682000.0 recorded in 2018.
  • Peak annual rise in Change in Account Payables hit 442.9% in 2018, while the deepest fall reached 256.69% in 2018.
  • Year by year, Change in Account Payables stood at -$1.4 million in 2017, then soared by 142.36% to $585000.0 in 2018, then soared by 33.16% to $779000.0 in 2019.
  • Business Quant data shows Change in Account Payables for VYNE at $779000.0 in Q4 2019, -$1.7 million in Q3 2019, and $921000.0 in Q2 2019.